drughunter.com
13 minute read
May 1, 2024

Schrödinger’s MALT1 Inhibitor Showcases the Potential of its Computational Platform and Becomes Its First In-House Clinical Compound

SGR-1505

oral, allosteric MALT1 inhibitor Ph. I compound for mature B cell neoplasm computer-aided drug design from literature starting point ACS Spring 2024 meeting presentation Schrödinger, New York, NY

Reviewer:  
Editor:  
Loading...

twitterlinkedinemail

Other molecules you may be interested in